ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1391

Ultrasound Response to Tocilizumab in Surgically Replaced Joints and Surgically Operated Joint Areas of Rheumatoid Arthritis Patients

Evan Choate1, Gurjit S. Kaeley2, Jenny Brook3, John Fitzgerald4, David Elashoff5 and Veena K. Ranganath6, 1David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, 2Rheumatology, University of Florida College of Medicine, Jacksonville, Jacksonville, FL, 3Medicine, David Geffen School of Medicine, UCLA, Los Angeles, CA, 4David Geffen School of Medicine, Division of Rheumatology, Department of Internal Medicine, University of California, Los Angeles, Los Angeles, CA, 5David Geffen School of Medicine,, University of California, Los Angeles, Los Angeles, CA, 6Medicine/Rheumatology, University of California, Los Angeles, Los Angeles, CA

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: outcomes, Rheumatoid arthritis and Ultrasound

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Rheumatoid Arthritis – Clinical Aspects Poster II: Pathophysiology, Autoantibodies, and Disease Activity Measures

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Rheumatoid Arthritis (RA) disease activity outcomes are used for treatment decisions (ie. DAS28-ESR). Surgically operated joints (SOJ) are assumed not to respond to therapy and are often not included in standard trials. This analysis examines whether a therapeutic benefit is conferred to SOJ over six months, as measured by grey-scale synovial hypertrophy (GSUS) and power Doppler (PDUS) synovitis scores.

Methods: 20 RA patients with SOJ enrolled in an open-label 24-week tocilizumab study. Participants’ joints were identified as SOJ (replaced, fusion, arthroscopy, tendon) or as a non-operated joint (NOJ). Joint assessments occurred at baseline, 1-mos, 3-mos, and 6-mos for: tender joint (0/1), swollen joint (0/1), GSUS (0-3), and PDUS (0-3). GSUS and PDUS images were captured for 32 joints including bilateral MCPs, PIPs, wrist, medial/lateral parapatellar knee recesses, and MTP 2-5. Maximum GSUS and PDUS scores across the views for each joint were calculated. Mean GSUS and PDUS scores from SOJ were compared to NOJ over time by mixed effects linear models analysis. GSUS and PDUS compared baseline to 6months using mixed effects models, while TJ and SJ used McNemar test.

Results: A significant difference between NOJ and SOJ over 6mos was seen for GSUS and PDUS (both p<0.0001) (Figure 1). There was a significant improvement in TJ for NOJ (p=0.02), however no difference seen in SOJ for SJ or TJ (Table 1). Of 37 SOJ joints assessed by ultrasound, 78% of joints had PDUS>1 and 86% of joints had GSUS>1 at baseline, while NOJ had 43% and 64% respectively. There was a significant GSUS response seen for the overall set of SOJ from baseline to 6-months (p=0.03), and a trend for PDUS (p=0.07).

Conclusion: RA activity measures such as DAS28-ESR require strict parameters to provide patient prognosis and treatment efficacy. Traditional trials exclude operated joints from measurement and analysis. This study suggests that SOJ joints exhibit significant synovitis. Response to tocilizumab over six months, by GSUS. Further research is needed to validate these findings, and this study suggests that ultrasound RA clinical studies should assess response in both SOJ and NOJ.


Disclosure: E. Choate, None; G. S. Kaeley, None; J. Brook, None; J. Fitzgerald, None; D. Elashoff, None; V. K. Ranganath, Genentech and Biogen IDEC Inc., 2,Pfizer Inc, 2,Bristol-Myers Squibb, 2,Bristol-Myers Squibb, 5.

To cite this abstract in AMA style:

Choate E, Kaeley GS, Brook J, Fitzgerald J, Elashoff D, Ranganath VK. Ultrasound Response to Tocilizumab in Surgically Replaced Joints and Surgically Operated Joint Areas of Rheumatoid Arthritis Patients [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/ultrasound-response-to-tocilizumab-in-surgically-replaced-joints-and-surgically-operated-joint-areas-of-rheumatoid-arthritis-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/ultrasound-response-to-tocilizumab-in-surgically-replaced-joints-and-surgically-operated-joint-areas-of-rheumatoid-arthritis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology